Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
SLS
vs
S&P 500
SLS
S&P 500
Over the past 12 months, SLS has significantly outperformed S&P 500, delivering a return of +498% compared to S&P 500's +16% growth.
Stocks Performance
SLS vs S&P 500
Performance Gap
SLS vs S&P 500
Performance By Year
SLS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sellas Life Sciences Group Inc
Glance View
Sellas Life Sciences Group is a clinical-stage biopharmaceutical company focused on cancer treatment. It develops drug candidates that aim to help the immune system attack tumors and to improve how certain hard-to-treat cancers are managed. Its work centers on oncology, with a pipeline of experimental therapies that are still going through testing and regulatory review. The company does not sell a broad range of commercial products. Instead, it advances its drug candidates through research, clinical trials, and, if successful, approval for use in patients. Its customers are not everyday consumers; its future buyers would be hospitals, cancer specialists, and health systems, while its current business can also involve research partnerships or licensing deals with larger drug makers. Sellas makes money the way many biotech developers do: through collaboration payments, licensing arrangements, and eventually product sales if one of its therapies reaches the market. What makes its model different is that it is building value mainly from a small number of specialized cancer drugs rather than from a large existing product line. That makes the company dependent on scientific results, regulatory decisions, and partnership interest from the oncology industry.